<DOC>
	<DOCNO>NCT00313599</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Lapatinib may help paclitaxel work well make tumor cell sensitive drug . Lapatinib may also stop growth tumor cell block enzymes need cell growth . Giving lapatinib together paclitaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lapatinib give together paclitaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Lapatinib Paclitaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) 2-day pulse lapatinib give prior paclitaxel ( albumin-stabilized nanoparticle formulation ) ( ABI-007 ; Abraxane™ ) patient advance solid tumor malignancy . Secondary - Define toxicity regimen . - Determine , preliminarily , antitumor efficacy safety ABI-007 precede 2-day pulse lapatinib . - Characterize potential molecular marker within circulate tumor cell marker response ( e.g. , HER2 AKT ) apoptotic marker . - Determine whether lapatinib give MTD prior ABI-007 alters pharmacokinetic property paclitaxel component ABI-007 . OUTLINE : This does-escalation study lapatinib . Patients stratify accord dose level . Patients receive oral lapatinib day 1 , 2 , 8 , 9 , 15 , 16 paclitaxel ( albumin-stabilized nanoparticle formulation ) ( ABI-007 ; Abraxane™ ) IV 30 minute day 3 , 10 , 17 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos lapatinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor , include follow tumor type : Breast cancer Nonsmall cell lung cancer Prostate cancer Bladder cancer Gastroesophageal junction cancer Ovarian cancer Germ cell tumor Advanced metastatic disease No effective curative therapy exist Evaluable disease Measurable disease require Boneonly disease allow No progress brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious intercurrent medical psychiatric illness No serious active infection No gastrointestinal tract disease would impair patient 's ability take oral medication No history significant cardiac disease , include follow : Congestive heart failure Symptomatic cardiac arrhythmia Unstable angina No preexist peripheral neuropathy ≥ 2 PRIOR CONCURRENT THERAPY : Any number prior therapy allow Prior paclitaxel , tyrosine kinase inhibitor therapy , endothelial growth factor inhibitor allow At least 14 day since prior concurrent CYP3A4 inducer herbal dietary supplement At least 7 day since prior concurrent CYP3A4 inhibitor At least 6 month since prior concurrent amiodarone More 1 month since prior chemotherapy , radiotherapy , hormonal therapy , investigational anticancer agent Concurrent continue use gonadal suppression agent ( i.e. , goserelin acetate leuprolide acetate ) allow No antacid 1 hour study drug administration No concurrent retinoids No concurrent hormonal anticancer agent No concurrent anticancer chemotherapy investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>ovarian choriocarcinoma</keyword>
	<keyword>ovarian dysgerminoma</keyword>
	<keyword>ovarian embryonal carcinoma</keyword>
	<keyword>ovarian yolk sac tumor</keyword>
	<keyword>ovarian mixed germ cell tumor</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
</DOC>